United States· US:71390-125_b4cf2d39-67e7-459b-add4-5454b1029c14
Barhemsys
A amisulpride product containing amisulpride, registered in United States by Acacia Pharma Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Amisulpride is registered in 14 of 19 countries.
Countries holding a registration under ATC N05AL05 (amisulpride), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Amisulpride · ATC N05AL05
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amisulpride costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $1.37 in France to $2.49 in Switzerland — a ×1.8 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amisulpride · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.49
- IT Italy$1.87
- FR France$1.37
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Amisulpride
- Manufacturer
- Acacia Pharma Ltd
- Country
- United States (US)
- ATC code
- N05AL05
- ATC class
- Amisulpride
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 2
- ndc11713901252010 CARTON in 1 PACKAGE (71390-125-20) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-21) / 2 mL in 1 VIAL, SINGLE-DOSE
- ndc11713901255010 CARTON in 1 PACKAGE (71390-125-50) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-51) / 4 mL in 1 VIAL, SINGLE-DOSE
Regulatory notes
Interactions
228 interactions on record for amisulpride.
Graded by severity as the source publishes them — 126 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amisulpride · interactions on record
228 records
- 126 severe
- 49 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- MetoclopramideA03FA01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
51 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amisulpride in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAmisulpride 100mg tabletsViatris UK Healthcare Ltd
- CzechiaAKTIPROLMedochemie Ltd., Limassol
- FranceAMISULPRIDE ARROW 100 mg, comprimé sécableARROW GENERIQUES
- BelgiumAlpridemylan 100 mgViatris GX
- SpainAMISULPRIDA APOTEX 400 mg COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFGApotex Europe B.V.
- PolandAmiprydPrzedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.
- NetherlandsAktiprol 100 mg tablettenProlepha Research B.V.
- SwitzerlandAmisulprid-Mepha
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Amisu, Solian
- Belgium · Amisulpride Eg, Solian
- Bulgaria · Alonet, Медосулпид
- Cyprus · Aktiprol, Solian
- Czechia · Aktiprol, Amilia
- Germany · Amisulprid Aaa, Amisulprid Mylan
- Denmark · Aktiprol, Amisulprid Dlf
- Estonia · Amisan, Solian
- Spain · Amisulprida Aurovitas, Amisulprida Normon
- France · Amisulpride Arrow Lab, Amisulpride Biogaran
- United Kingdom (Northern Ireland) · Amisulpride, Amisulpride Accord-Uk
- Greece · Isofredil, Nodasic
- Croatia · Aktiprol, Solian
- Hungary · Amisulprid Ratiopharm, Amitrex
- Ireland · Amisulpride Mylan, Solian
- Iceland · Solian
- Italy · Amisulpride Aurobindo, Amisulpride Doc
- Lithuania · Aktiprol, Amisan
- Luxembourg · Amisulpride Eg, Solian
- Latvia · Aktiprol, Solian
- Malta · Aktiprol, Amisulpride Syri Pharma
- Netherlands · Aktiprol
- Norway · Solian
- Poland · Amipryd, Amisan
- Portugal · Amissulprida Aurobindo, Amissulprida Aurovitas
- Romania · Masultab, Midora
- Slovenia · Solian
- Slovakia · Aktiprol, Amisulprid Viatris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cdfe37bc-d8f9-46c4-b35d-d901197272f3 GET /v1/drugs/cdfe37bc-d8f9-46c4-b35d-d901197272f3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "8110R61I4U",
"rxcui": "46303",
"inchikey": "NTJOBXMMWNYJFB-UHFFFAOYSA-N",
"display_name": "AMISULPRIDE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "INTRAVENOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"ab23bc6e-b6a8-165f-e053-2a95a90ab144": {
"match": "brand_token",
"title": "BARHEMSYS (AMISULPRIDE) INJECTION, SOLUTION [ACACIA PHARMA LTD]",
"spl_version": "7",
"published_date": "2025-06-11"
}
},
"productid": "71390-125_b4cf2d39-67e7-459b-add4-5454b1029c14",
"productndc": "71390-125",
"dosage_form": "INJECTION, SOLUTION",
"orange_book": {
"appl_no": "209510",
"products": [
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "5MG/2ML (2.5MG/ML)",
"product_no": "001",
"approval_date": "Feb 26, 2020"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "10MG/4ML (2.5MG/ML)",
"product_no": "002",
"approval_date": "Sep 1, 2020"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "AMISULPRIDE",
"proprietary_name": "Barhemsys",
"active_ingred_unit": "mg/mL",
"application_number": "NDA209510",
"marketing_category": "NDA",
"nonproprietary_name": "Amisulpride",
"start_marketing_date": "20200227",
"active_numerator_strength": "2.5"
}See everything about amisulpride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.